US2003220395A1PendingUtilityA1

Treatment of ocular hypertension and glaucoma

49
Individually held — no corporate assignee on recordPriority: Jul 20, 2000Filed: Mar 12, 2003Published: Nov 27, 2003
Est. expiryJul 20, 2020(expired)· nominal 20-yr term from priority
Inventors:Ryuji Ueno
A61P 27/02A61P 27/06A61K 31/5575
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

15-keto latanoprost and other 15-keto prostaglandin analogs are used as ocularly applied intraocular pressure reducing agents.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method for reducing intraocular pressure or for treating glaucoma which comprises topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester in a dose below the known dose for the corresponding 15-OH compound.  
     
     
         2 . The method of  claim 1  wherein the compound administered is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester.  
     
     
         3 . The method of  claim 1  wherein the dose is about 0.05 to 0.750 μg per eye.  
     
     
         4 . The method of  claim 3  wherein the dose is about 0.075 to 0.250 μg per eye.  
     
     
         5 . The method of  claim 4  wherein the dose is about 0.100 to below 0.175 μg per eye.  
     
     
         6 . A method for reducing intraocular pressure or for treating glaucoma which comprising topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester in a dose of about 0.050 to below 5.0 μg per eye.  
     
     
         7 . The method of  claim 6  wherein the compound administered is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester.  
     
     
         8 . The method of  claim 6  wherein the dose is about 0.10 to 4.5 μg per eye.  
     
     
         9 . The method of  claim 8  wherein the dose is about 0.50 to 2.5 μg per eye.  
     
     
         10 . The method of  claim 9  wherein the dose is about 1.0 to 2.0 μg per eye.  
     
     
         11 . The method of  claim 1  or  claim 6  wherein the compound is applied one or two times a day.  
     
     
         12 . The method of  claim 1  or  claim 6  wherein the dose is about one-tenth the usual dose of the corresponding 15-OH compound.  
     
     
         13 . The method of  claim 2  or  claim 7  wherein the dose is about one-tenth the usual dose of latanoprost.  
     
     
         14 . The method of  claim 1  or  claim 6  wherein the mammal is a human.  
     
     
         15 . The method for maintaining a reduced intraocular pressure by periodic administration to a mammal as a topically applied ocular eye drop, an effective amount of a compound selected from the group consisting of 15-oxo-16-(3-trifluofomethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester.  
     
     
         16 . A method of  claim 15  wherein the compound administerd is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α isopropyl ester.  
     
     
         17 . The method of  claim 15  wherein the dose is about 0.050 to 0.750 μg per eye.  
     
     
         18 . The method of  claim 17  wherein the dose is about 0.075 to 0.250 μg per eye.  
     
     
         19 . The method of  claim 18  wherein the dose is about 0.100 to 0.175 μg per eye.  
     
     
         20 . The method of  claim 15  wherein the dose is about 0.050 to below 5.0 μg per eye.  
     
     
         21 . The method of  claim 20  wherein the dose is about 0.10 to 4.50 μg per eye.  
     
     
         22 . The method of  claim 21  wherein the dose is about 0.50 to 2.5 μg per eye.  
     
     
         23 . The method of  claim 22  wherein the dose is about 1.0 to 2.0 μg per eye.  
     
     
         24 . The method of  claim 15  wherein the compound is applied one or two times a day.  
     
     
         25 . The method of  claim 15  wherein intraocular pressure is initially reduced by application of a 15-OH compound.  
     
     
         26 . The method of  claim 25  wherein intraocular pressure is initially reduced by application of latanoprost.  
     
     
         27 . The method of  claim 15  wherein the mammal is a human.  
     
     
         28 . A method for reducing intraocular pressure or for treating glaucoma which comprises topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-17-phenyl-18,19,20 trinor PGF 2 α N-ethylamide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α N-ethylamide.  
     
     
         29 . The method of  claim 28  wherein the dose is about one-tenth the usual dose of the corresponding 15-OH compound.  
     
     
         30 . The method of  claim 28  wherein the mammal is a human.  
     
     
         31 . The method for maintaining a reduced intraocular pressure by periodic administration to a mammal as a topically applied ocular eye drop, an effective amount of a compound selected from the group consisting of 15-oxo-17-phenyl-18,19,20 trinor PGF 2 α N-ethylamide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 α N-ethylamide.  
     
     
         32 . The method of  claim 31 , wherein the compound is applied one or two times a day.  
     
     
         33 . The method of  claim 28  wherein the dose is about 0.05 to 15μg per eye.  
     
     
         34 . The method of  claim 33  wherein the dose is about 0.10 to 10 μg per eye.  
     
     
         35 . The method of  claim 34  wherein the dose is is about 0.50 to 8.0 μg per eye.  
     
     
         36 . The method of  claim 35  wherein the dose is about 1.0 to 6.0 μg per eye.  
     
     
         37 . The method of  claim 31  wherein the dose is about 0.05 to 15 μg per eye.  
     
     
         38 . The method of  claim 37  wherein the dose is about 0.10 to 10 μg per eye.  
     
     
         39 . The method of  claim 38  wherein the dose is about 0.50 to 8.0 μg per eye.  
     
     
         40 . The method of  claim 39  wherein the dose is about 1.0 to 6.0 μg per eye.  
     
     
         41 . The method of  claim 31  wherein the compound is applied one or two times a day.  
     
     
         42 . The method of  claim 31  wherein the intraocular pressure is initially reduced by application of a 15-OH compound.  
     
     
         43 . The method of  claim 31  wherein the mammal is a human.  
     
     
         44 . The method of  claim 1  wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester.  
     
     
         45 . The method of  claim 6  wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester.  
     
     
         46 . The method of  claim 15  wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 α isopropyl ester.

Join the waitlist — get patent alerts

Track US2003220395A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.